Previously, our team also found that miR-34a inhibited the proliferation and migration of breast cancer cells by downregulating Bcl-2 and SIRT118, and we have developed the T-VISA-miR-34a which may provide a useful, specific, and safe targeted therapeutic strategy for breast cancer19. Here, BCL2 is linked to breast carcinoma.